Last updated: April 10, 2024
Sponsor: MemorialCare Health System
Overall Status: Active - Recruiting
Phase
N/A
Condition
Hormone Deficiencies
Diabetes (Pediatric)
Primary Insulin Hypersecretion
Treatment
Dexcom G6 continuous glucose monitor
Clinical Study ID
NCT06363929
341-23
Ages 24-3 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age: 0-90 days old
- Gestational Age: > 28 weeks gestational age
- Diagnosis of hyperinsulinism based on critical sample and/or glucagon challenge
Exclusion
Exclusion Criteria:
- Diffuse skin disease such that placement of a Dexcom G6 sensor would be difficult tosecure
- Infants colonized or infected with multi-drug resistant organisms (i.e. MRSA, VRE,ESBL producing bacteria)
- Infants on hypothermic protocols
- Infants expected to remain in the NICU <24 hours
- Infants enrolled in a competing clinical trial
- Family/team have decided to limit or redirect from aggressive NICU technologicalsupport
- Ward of the state
Study Design
Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Dexcom G6 continuous glucose monitor
Phase:
Study Start date:
June 01, 2023
Estimated Completion Date:
December 31, 2025
Connect with a study center
Miller Children's Hospital
Long Beach, California 90806
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.